Product
Mouse Anti-SEMA4D Monoclonal Antibody (CBP2806)
[CAT#: NAB20101883CR]
Mouse Monoclonal (1C1A6) to SEMA4D
- Host Species:
- Mouse
- Species Reactivity:
- Human
- Applications:
- IHC; WB; ELISA
Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
SPECIFIC INQUIRY
inquiryProduct Overview
Description
CD100 belongs to the family of immune semaphorins, and CD100 is abundantly expressed on resting T cells, NK cells, and antigen-presenting cells. As a transmembrane glycoprotein, it is digested to its soluble form, sCD100, by specific matrix metalloproteinases. CD100 has been reported that the expression levels of CD100, and one of its receptors, plexin-B1 (PLXNB1), are increased in head and neck, prostate, colon, breast, and lung cancers, and the interaction between them provides oncogenic signaling essential for tumor growth and metastasis.
Expression Host
Mammalian cells
Immunogen
CD100 fusion protein Ag26461
Species Reactivity
Human
Clonality
Monoclonal
Host Species
Mouse
Isotype
IgG1
Clone Number
CBP2806
Applications
IHC; WB; ELISA
Application Notes
IHC : 1:20-1:200; WB : 1:500-1:1000
Research Areas
Neural Signal Transduction
Conjugation
Unconjugated
Product Properties
Form
Liquid
Formulation
PBS, 0.1% sodium azide and 50% glycerol pH 7.3.
Preservatives
Yes
Concentration
1000 μg/ml
Purification
Antigen affinity purification
Purity
>95%, as determined by SDS-PAGE
Shipping
The product is shipped at 4°C. Upon receipt, store it immediately at the temperature recommended below.
Storage
Store at -20°C. Stable for one year after shipment.
Research Use Only
For research use only, not for diagnostic or therapeutic use.
Target
Publications
Publications (0)
Neural Antibodies
For Research Use Only. Not For Clinical Use.
